Reports indicate that kidney and brain targeting is also achievable through glycotargeting.89–92 Glucose transporters (GLUT), such as GLUT1 and GLUT3, are overexpressed in various cancer cells, which can be targeted for anticancer therapy and immunodiagnostic markers.89–92 It has been found that the overexpression of GLUT1 is associated with tumour progression and the reduced expression of GLUT1 suppresses the tumour growth in vitro and in vivo. This evidence concerns the gene SLC2A1 and cancer.